AVALO THERAPEUTICS, INC. (AVTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $53.00K; Additional Paid in CapitalUSD $953.70M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-583.00K; Retained Earnings (Accumulated Deficit)USD $-504.51M.
- 2026-03-31: Common Stock, Value, IssuedUSD $25.00K; Additional Paid in CapitalUSD $536.45M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.00K; Retained Earnings (Accumulated Deficit)USD $-468.15M.
- 2025-12-31: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in CapitalUSD $531.49M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $68.00K; Retained Earnings (Accumulated Deficit)USD $-448.52M.
- 2025-09-30: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in CapitalUSD $526.29M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $41.00K; Retained Earnings (Accumulated Deficit)USD $-434.80M.
AVALO THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Preferred Stock, Value, Issued USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $53.00K | $953.70M | $-583.00K | $-504.51M | $448.66M | 3 month · $5.31M 6 month · $8.88M | (m) | (m) | (m) |
| 2026-03-31 | $25.00K | $536.45M | $-6.00K | $-468.15M | $68.32M | 3 month · $3.58M | (m) | (m) | (m) |
| 2025-12-31 | $18.00K | $531.49M | $68.00K | $-448.52M | $83.05M | 12 month · $13.62M | (m) | (m) | (m) |
| 2025-09-30 | $18.00K | $526.29M | $41.00K | $-434.80M | $91.55M | 3 month · $3.15M 9 month · $9.11M | (m) | (m) | (m) |
| 2025-06-30 | $11.00K | $508.77M | $-34.00K | $-404.18M | $104.57M | 3 month · $2.72M 6 month · $5.96M | (m) | (m) | (m) |
| 2025-03-31 | $11.00K | $506.02M | (m) | $-383.41M | $122.61M | 3 month · $3.24M | (m) | (m) | (m) |
| 2024-12-31 | $10.00K | $503.29M | $0.00 | $-370.26M | $133.03M | 12 month · $5.85M | (m) | (m) | (m) |
| 2024-09-30 | $10.00K | $355.99M | (m) | $-334.92M | $21.08M | 3 month · $1.85M 9 month · $2.95M | (m) | (m) | (m) |
| 2024-06-30 | $1.00K | $344.35M | (m) | $-357.96M | $-13.61M | 3 month · $471.00K 6 month · $1.10M | (m) | (m) | (m) |
| 2024-03-31 | $1.00K | $343.88M | (m) | $-456.42M | $-112.54M | 3 month · $629.00K | (m) | (m) | (m) |
| 2023-12-31 | $1.00K | $342.44M | (m) | $-335.13M | $7.30M | 12 month · $3.48M | 12 month · $3.64M | (m) | (m) |
| 2023-09-30 | $192.00K | $341.47M | (m) | $-326.97M | $14.70M | 3 month · $953.00K 9 month · $2.70M | 9 month · $3.64M | (m) | (m) |
| 2023-06-30 | $14.00K | $314.75M | (m) | $-321.74M | $-6.97M | 3 month · $893.00K 6 month · $1.75M | 3 month · $3.64M 6 month · $3.64M | (m) | 3 month · $893.00K 6 month · $1.75M |
| 2023-03-31 | $13.00K | $307.50M | (m) | $-313.78M | $-6.27M | 3 month · $855.00K | (m) | (m) | 3 month · $855.00K |
| 2022-12-31 | $0.00 | $292.91M | (m) | $-303.82M | $-10.91M | 12 month · $7.55M | (m) | (m) | 12 month · $7.55M |
| 2022-09-30 | $9.00K | $291.98M | (m) | $-294.01M | $-2.03M | 3 month · $731.00K 9 month · $6.71M | (m) | (m) | 3 month · $731.00K 9 month · $6.71M |
| 2022-06-30 | $9.00K | $291.24M | (m) | $-297.20M | $-5.95M | (m) | (m) | (m) | 3 month · $669.00K 6 month · $5.98M |
| 2022-03-31 | $113.00K | $290.45M | (m) | $-284.22M | $6.34M | (m) | (m) | (m) | 3 month · $5.31M |
| 2021-12-31 | $9.00K | $285.24M | (m) | $-262.17M | $23.08M | (m) | 12 month · $861.00K | $0.00 | 12 month · $8.17M |
| 2021-09-30 | $112.00K | $283.17M | (m) | $-242.97M | $40.31M | (m) | 9 month · $861.00K | $0.00 | 3 month · $1.76M 9 month · $6.28M |
| 2021-06-30 | $96.00K | $247.07M | (m) | $-225.57M | $21.59M | (m) | 3 month · $861.00K 6 month · $861.00K | $0.00 | 3 month · $3.07M 6 month · $4.52M |
| 2021-03-31 | $89.00K | $241.53M | (m) | $-208.47M | $33.16M | (m) | 3 month · $4.40M | $1.00K | 3 month · $1.45M |
| 2020-12-31 | $75.00K | $202.28M | (m) | $-177.79M | $24.56M | (m) | (m) | $1.00K | 12 month · $6.79M |
| 2020-09-30 | $74.90K | $200.64M | (m) | $-162.15M | $38.57M | (m) | (m) | $1.26K | 3 month · $1.45M 9 month · $5.35M |
| 2020-06-30 | $74.90K | $199.19M | (m) | $-148.69M | $50.58M | (m) | (m) | $1.26K | 3 month · $2.79M 6 month · $3.90M |
| 2020-03-31 | $59.56K | $160.94M | (m) | $-135.41M | $25.59M | (m) | (m) | $1.26K | 3 month · $1.12M |
| 2019-12-31 | $44.38K | $135.24M | (m) | $-114.29M | $21.00M | (m) | (m) | $2.86K | 12 month · $2.46M |
| 2019-09-30 | $44.11K | $134.09M | (m) | $-115.91M | $18.22M | (m) | (m) | $2.86K | 3 month · $818.79K 9 month · $1.94M |
| 2019-06-30 | $42.90K | $129.55M | (m) | $-111.90M | $17.70M | (m) | (m) | $2.86K | 3 month · $526.71K 6 month · $1.12M |
| 2019-03-31 | $42.75K | $128.75M | (m) | $-105.67M | $23.12M | (m) | (m) | $2.86K | 3 month · $596.69K |
| 2018-12-31 | $40.80K | $119.08M | (m) | $-98.22M | $20.91M | (m) | (m) | $2.86K | 12 month · $2.43M |
| 2018-09-30 | $40.66K | $112.13M | (m) | $-92.66M | $19.51M | (m) | (m) | $0.00 | 3 month · $945.13K 9 month · $1.80M |
| 2018-06-30 | $33.79K | $87.24M | (m) | $-68.06M | $19.22M | (m) | (m) | $0.00 | 3 month · $608.43K 6 month · $851.25K |
| 2018-03-31 | $31.41K | $83.94M | (m) | $-62.05M | $24.58M | (m) | (m) | $0.00 | 3 month · $242.82K |
| 2017-12-31 | $31.27K | $83.34M | (m) | $-58.17M | $27.86M | (m) | (m) | $0.00 | 12 month · $1.16M |
| 2017-09-30 | $26.05K | $77.17M | (m) | $-55.07M | $22.12M | (m) | (m) | $0.00 | (m) |
| 2017-06-30 | $14.12K | $76.92M | (m) | $-73.79M | $3.14M | (m) | (m) | $4.00 | (m) |
| 2017-03-31 | $10.90K | $71.56M | (m) | $-72.00M | $-425.76K | (m) | (m) | (m) | (m) |
| 2016-12-31 | $9.43K | $70.23M | (m) | $-70.04M | $207.00K | (m) | (m) | $0.00 | 12 month · $1.69M |
| 2016-09-30 | $9.07K | $68.97M | (m) | $-68.40M | $586.83K | (m) | (m) | (m) | (m) |
| 2016-06-30 | $8.65K | $67.79M | (m) | $-62.23M | $5.57M | (m) | (m) | (m) | (m) |
| 2016-03-31 | $8.65K | $67.58M | (m) | $-58.70M | $8.88M | (m) | (m) | (m) | (m) |
| 2015-12-31 | $8.65K | $66.64M | (m) | $-53.56M | $13.08M | (m) | (m) | $0.00 | 12 month · $394.75K |
| 2015-09-30 | $650.00 | $17.06M | (m) | $-49.91M | $-32.85M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $650.00 | $16.74M | (m) | $-43.07M | $-26.33M | (m) | (m) | (m) | 12 month · $1.09M |
| 2013-12-31 | (m) | (m) | (m) | (m) | $-17.85M | (m) | (m) | (m) | 12 month · $748.65K |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-11.38M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |